GCYA3抗体;GCYA3 Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of GCYA3 expression in Human fetal kidney lysate.    

  
  

The GCYA3 antibody is designed to target guanylyl cyclase A3 (GC-A3), a membrane-bound receptor enzyme that plays a critical role in cellular signaling by converting GTP to cyclic GMP (cGMP). GC-A3 is part of the natriuretic peptide receptor family, primarily binding atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) to regulate blood pressure, fluid homeostasis, and cardiovascular function. Dysregulation of GC-A3 activity has been implicated in hypertension, heart failure, and renal disorders, making it a focus of cardiovascular and metabolic research.

The GCYA3 antibody is typically developed in animal models (e.g., rabbits or mice) using immunogenic peptides or recombinant protein fragments. It enables detection and quantification of GC-A3 expression in tissues like the heart, kidneys, and vasculature via techniques such as Western blotting, immunohistochemistry, and ELISA. Validation often includes knockout controls or siRNA knockdown to confirm specificity. Researchers utilize this tool to explore GC-A3's signaling mechanisms, its interaction with ligands, and its pathophysiological roles in disease models. Recent studies also investigate its potential as a therapeutic target, particularly in conditions linked to cGMP pathway dysfunction.